| VOR | VRTX | REGN | VRNA | ARGX | ALNY | |
|---|---|---|---|---|---|---|
| Company Name | Vor Biopharma Inc. | Vertex Pharmaceuticals Incorporated | Regeneron Pharmaceuticals, Inc. | Verona Pharma plc | argenx SE | Alnylam Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare | Healthcare | Healthcare | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $56.06M | $116.06B | $76.56B | $72.68B | $53.66B | $52.51B |
| Employees | 0.16K | 6.10K | 15.16K | 0.21K | 1.60K | 2.23K |
| CEO | Jean-Paul Kress | Reshma Kewalramani | Leonard S. Schleifer | David S. Zaccardelli | Timothy Van Hauwermeiren | Yvonne L. Greenstreet |